Loading
Immuneering Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Zeskind Benjamin J., was filed 24 Jun 2026.
Immuneering Corp: what insiders have been doing
Every trade that managers of Immuneering Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 6 insiders have disclosed 7 filings since 19 October 2025.
The flow runs one way only: 6 insiders bought (6 purchases totalling €201k) and nobody sold on the market. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Schall Thomas J. filed the largest purchase, €87k, on 20 January 2026. On the buying side, the filings list 5 senior executives and 1 chief executive among the declarants.
The data flag 4 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 24 June 2026, 117 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 7 filings, this issuer sits below that mark. Our records for Immuneering Corp go back to 2021, with 42 purchases and 2 sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
64
Thresholds
n/a
Buy Volume
€1M
42 ops. · all time
Sell Volume
€1M
2 ops. · all time
Who traded when
BuySalePeter Feinberg5 buys
Benjamin J. Zeskind3 buys
Leah R. Neufeld3 buys
Thomas J. Schall3 buys
Brett Matthew Hall2 buys
Harold Eugene Brakewood2 buys
+3 other insiders
Since the insiders bought
- -19.6%Entry US$4.53 · Close 15 Oct 2026 US$3.64
- +10.3%Entry US$5.34 · Close at T+90 US$5.89
- +14.4%Entry US$4.85 · Close at T+90 US$5.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.56
Analyst consensus
6 analysts1.29/5
US$12.00Target US$17.17(+382%)US$30.00
Income statement
EBITDA-US$59M
Net income-US$56M0.0% margin
Valuation
PER (forward)-2.8x
P/Book1.2x
Beta0.46
Balance sheet & cash
Market capUS$230.3M
Total debtUS$3.8M
Free Cash Flow-US$45.5M
Debt / Equity2%
Profitability & ownership
ROE-52.1%
ROA-32.8%
% insiders13.8%
% institutions55.4%
Last declaration on 24 June 2026
Declarations64 total
2,400 sharesClass A Common StockSEC:0001790340-26-000078:0
Canonical exit: 21 Sept 2026 (T+90)
3,628 shares@ US$4.292525.5% of flowClass A Common StockSEC:0001790340-26-000044:0
5,250 shares@ US$4.7661.6% of flowClass A Common StockSEC:0001790340-26-000016:0
Canonical exit: 16 Apr 2026 (T+90)
21,645 shares@ US$4.668143.2% of flowClass A Common StockSEC:0001790340-26-000014:0
Canonical exit: 15 Apr 2026 (T+90)
2,298 shares@ US$4.5712.8% of flowClass A Common StockSEC:0001790340-26-000012:0
Canonical exit: 15 Apr 2026 (T+90)
2,626 shares@ US$4.15317.7% of flowClass A Common StockSEC:0001790340-26-000010:0
Canonical exit: 13 Apr 2026 (T+90)
20,000 shares@ US$4.345211.6% of flowClass A Common StockSEC:0001790340-26-000008:0
Canonical exit: 12 Apr 2026 (T+90)
7,500 shares@ US$6.676.6% of flowClass A Common StockSEC:0001790340-25-000127:0
Canonical exit: 1 Jan 2026 (T+90)
300 shares@ US$6.395.1% of flowClass A Common StockSEC:0001790340-25-000125:0
Canonical exit: 30 Dec 2025 (T+90)
800 shares@ US$6.37928.2% of flowClass A Common StockSEC:0001790340-25-000123:0
Canonical exit: 30 Dec 2025 (T+90)
1,020 shares@ US$6.829919.5% of flowClass A Common StockSEC:0001790340-25-000121:0
Canonical exit: 30 Dec 2025 (T+90)
7,500 shares@ US$7.03076.9% of flowClass A Common StockSEC:0001790340-25-000119:0
Canonical exit: 29 Dec 2025 (T+90)
5,000 shares@ US$7.184.7% of flowClass A Common StockSEC:0001790340-25-000117:0
Canonical exit: 28 Dec 2025 (T+90)
11,815 shares@ US$1.42827.1% of flowClass A Common StockSEC:0001790340-25-000115:0
14,497 shares@ US$1.42854.6% of flowClass A Common StockSEC:0001790340-25-000113:0
14,880 shares@ US$1.42825.6% of flowClass A Common StockSEC:0001790340-25-000111:0
2,500 shares@ US$3.5956100.0% of flowClass A Common StockSEC:0001790340-25-000098:0
Canonical exit: 30 Sept 2025 (T+90)
700 shares@ US$3.56954.0% of flowClass A Common StockSEC:0001790340-25-000096:0
Canonical exit: 30 Sept 2025 (T+90)
2,985 shares@ US$3.37924.7% of flowClass A Common StockSEC:0001790340-25-000094:0
Canonical exit: 29 Sept 2025 (T+90)
9,500 shares@ US$3.661914.8% of flowClass A Common StockSEC:0001790340-25-000089:0
Canonical exit: 25 Sept 2025 (T+90)
7,415 shares@ US$2.699924.6% of flowClass A Common StockSEC:0001790340-25-000087:0
Canonical exit: 18 Sept 2025 (T+90)
1,900 shares@ US$2.528512.0% of flowClass A Common StockSEC:0001790340-25-000085:0
Canonical exit: 18 Sept 2025 (T+90)
25,000 shares@ US$2.52758.5% of flowClass A Common StockSEC:0001790340-25-000083:0
Canonical exit: 16 Sept 2025 (T+90)
21,000 shares@ US$2.387823.8% of flowClass A Common StockSEC:0001790340-25-000081:0
Canonical exit: 16 Sept 2025 (T+90)
40,485 shares@ US$2.205238.7% of flowClass A Common StockSEC:0001790340-25-000079:0
Canonical exit: 15 Sept 2025 (T+90)
25 of 64 declarations
About Immuneering Corp
Immuneering Corp is a US-based biotechnology company listed on the Nasdaq (United States) under the ticker IMRX. It is positioned as a clinical-stage oncology company, focused on developing cancer therapies intended to improve both survival and tolerability for patients. Headquartered in Cambridge, Massachusetts, the company was built around a computational biology and signaling-dynamics approach to drug discovery, with the goal of designing medicines that can suppress tumor pathways while limiting damage to healthy cells. For international investors, this is a classic development-stage biopharma story: high execution and clinical risk, but meaningful upside if its lead programs continue to deliver convincing data. ([ir.immuneering.com](https://ir.immuneering.com/investor-relations?utm_source=openai))
Immuneering’s core value proposition is its “Deep Cyclic Inhibitors” platform, which the company describes as a pulsed pathway-inhibition strategy designed to outpace tumor adaptation. Its lead candidate is atebimetinib, also referred to as IMM-1-104, an oral, once-daily MEK inhibitor. Management has highlighted the program’s potential in MAPK pathway-driven cancers, including pancreatic cancer and other solid tumors with RAS mutations. The company also maintains earlier-stage programs, giving it a limited but relevant degree of pipeline diversification. ([ir.immuneering.com](https://ir.immuneering.com/investor-relations?utm_source=openai))
Read moreShow less
From a competitive standpoint, Immuneering operates in a crowded oncology landscape dominated by large pharmaceutical companies, specialty oncology biotechs, and multiple targeted-therapy platforms. Its differentiation is less about scale and more about its scientific approach and the possibility of addressing sizeable underserved patient populations. In theory, the platform’s multi-indication potential could broaden the opportunity set beyond a single tumor type. In practice, however, the equity story remains highly dependent on clinical readouts, tolerability, and the company’s ability to keep funding development through the next stages of the pipeline. ([ir.immuneering.com](https://ir.immuneering.com/investor-relations?utm_source=openai))
Geographically, Immuneering’s footprint is primarily US-centric, with its operational and scientific base in the Cambridge, Massachusetts area. Recent milestones underscore a capital-markets and clinical-development heavy phase: updates from the Phase 2a trial of IMM-1-104 in first-line pancreatic cancer, investor conference participation, and substantial financing activity in 2025, including a private placement and a large equity offering to support preclinical and clinical advancement. For investors in Europe, IMRX should be viewed as a speculative growth name driven by clinical catalysts and regulatory milestones, but one with a clearly articulated scientific thesis and increasing visibility in the oncology space. ([ir.immuneering.com](https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
